DOI:
10.1055/s-00000022
Das Gesundheitswesen
LinksClose Window
References
Courtney AE, McNamee PT, Maxwell AP.
Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients.
Nephron Clin Pract 2007;
107: c14-c19
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.